Author

Jean-Frederic Colombel 1

1 Icahn School of Medicine a

A COMBINATION OF CLINICAL, SEROLOGICAL AND GENETIC FACTORS PREDICTS COMPLICATED DISEASE COURSE IN PAEDIATRIC-ONSET CROHN'S DISEASE: RESULTS FROM A POPULATION-BASED STUDY

Hélène Sarter, Guillaume Savoye, Dominique Turck, Francis Vasseur, Guillemette Marot, Benjamin Pariente, Jean-Frederic Colombel, Corinne Gower-Rousseau, Mathurin Fumery

A HIGHER INDUCTION DOSING REGIMEN OF ADALIMUMAB DOES NOT ENHANCE MODULATION OF DOWNSTREAM BLOOD MOLECULAR MARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE OR ULCERATIVE COLITIS: RESULTS FROM THE SERENE-CD AND SERENE-UC STUDIES

Marc Ferrante, Valerie Pivorunas, James Butler, Naim Mahi, Nael M. Mostafa, Melanie Ruzek, James Fann, Feng Hong, Xiaohong Cao, Nizar Smaoui, Justin Wade Davis, Jasmina Kalabic, Alexandra Song, Heath M. Guay, Florian Rieder, Julian Panés, Jean-Frédéric Colombel

A RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO EXPLORE THE EFFICACY OF ORAL GED-0301 (MONGERSEN) ON ENDOSCOPIC ACTIVITY AND CLINICAL EFFECTS IN BOTH TNF-NAIVE AND TNF-EXPERIENCED SUBJECTS WITH ACTIVE CROHN?S DISEASE

Brian G. Feagan, Bruce E. Sands, Guillermo Rossiter, Xiaobin Li, Keith Usiskin, Xiaojiang Zhan, Jean-Frederic Colombel

A TREAT TO TARGET APPROACH DECREASES THE RATE OF CD-RELATED ADVERSE OUTCOMES VERSUS A CLINICAL APPROACH IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHN'S DISEASE: DATA FROM CALM

Jean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, Filip Baert, T. Vanásek, Ahmet Danalıoğlu, Gottfried Novacek, Alessandro Armuzzi, Xavier Hebuterne, Simon Travis, Silvio Danese, Walter Reinisch, William Sandborn, Paul Rutgeerts, Daniel W. Hommes, Stefan Schreiber, Ezequiel Neimark, Bidan Huang, Qian Zhou, Wan J Le

AbbVie - Are we ready to change the course of IBD?

Edouard Louis, Remo Panaccione, Laurent Peyrin-Biroulet, Jean-Frederic Colombel

Amgen - The emerging treatment landscape of IBD: role of innovator biologics and biosimilars (Amgen Europe GmbH)

Alessandro Armuzzi, Jean-Frederic Colombel, Walter Reinisch

AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Geert R. D'Haens, Brian Feagan, William J. Sandborn, Remo Panaccione, Julian Panés, Tadakazu Hisamatsu, Marc Ferrante, Ezequiel Neimark, Peter Bossuyt, Silvio Danese, Alexandra Song, Xiaomei Liao, Tian Feng, Rachel Duan, Sofie Berg, Jean-Frédéric Colombel, Kori Wallace

ANTI-TNFΑ TREATMENT EFFICACY IN PREVENTION OF POSTOPERATIVE RECURRENCE IN CROHN’S DISEASE DEPENDS ON PREVIOUS EXPOSURE TO ANTI-TNFΑ AGENTS

Michael Collins, Hélène Sarter, Corinne Gower-Rousseau, Dine Koriche, Maria Nachury, Louise Libier, Antoine Cortot, Philippe Zerbib, Jean-Frederic Colombel, Laurent Peyrin-Biroulet, Pierre Desreumaux, Guillaume Pineton de Chambrun

Association of Ustekinumab Serum Concentrations and Perianal Fistula Resolution in the Crohn's Disease UNITI Program

Bruce E. Sands, Brian Kramer, Christopher Gasink, Douglas Jacobstein, Long-Long Gao, Tony Ma, Joseph Adedokun, Jean-Frédéric Colombel, David A Schwartz

AZATHIOPRINE DOSE REDUCTION  INFLAMMATORY BOWEL DISEASE PATIENTS ON COMBINATION THERAPY: A PROSPECTIVE STUDY

Emilie Del Tedesco, Stéphane Paul, hubert marotte, Nicolas Williet, Jean Marc Phelip, Laurent Peyrin-Biroulet, Jean-Frederic Colombel, Xavier Roblin

Item 1 - 10 / 177
1
2 3 4 5 6 7
...
17 18